Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review

Patients with inflammatory bowel disease (IBD) are at increased risk of developing Pneumocystis jirovecii pneumonia (PJP) than the general population. Many medications utilized for the treatment of IBD affect the immune system, potentially further increasing the risk of PJP. Recommendations for prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Sierra, Caroline M., Daiya, Krishna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review of Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828113/
https://www.ncbi.nlm.nih.gov/pubmed/36222368
http://dx.doi.org/10.1002/phar.2733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828113/
https://www.ncbi.nlm.nih.gov/pubmed/36222368
http://dx.doi.org/10.1002/phar.2733

Ejemplares similares